The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
Abstract
PURPOSE: To perform a double-blind randomized trial with American Joint Commission on Cancer (AJCC) stage III melanoma patients for the following reasons: (1) to confirm our previous finding that patients with antibodies against the melanoma differentiation antigen GM2 have an improved prognosis, and (2) to demonstrate clinical benefit from GM2 antibody induction. PATIENTS AND METHODS: One hundred twenty-two patients with AJCC stage III melanoma who were free of disease after surgery were randomized: 58 to receive treatment with the GM2/BCG vaccine, and 64 to receive treatment with bacille Calmette-Guèrin (BCG) alone. All patients were pretreated with low-dose cyclophosphamide (Cy). RESULTS: GM2 antibody was detected in 50 of 58 patients treated with GM2/BCG and seven of 64 patients treated with BCG alone. With a minimum follow-up period of 51 months, there was a highly significant increase in the disease-free interval (P = .004) and a 17% increase in overall survival (P = .02) in these 57 antibody-positive patients, confirming our earlier experience. Exclusion of all patients with preexisting GM2 antibodies (one in the GM2/BCG group and five in the BCG group) from statistical analysis resulted in a 23% increase in disease-free interval (P = .02) and a 14% increase in overall survival (P = .15) at 51 months for patients treated with the GM2/BCG vaccine. However, when all patients in the two treatment groups were compared as randomized, these increases were 18% for disease-free interval and 11% for survival in the GM2/BCG treatment group, with neither result showing statistical significance. CONCLUSION: (1) Vaccination with GM2/BCG induced immunoglobulin M (IgM) antibodies in most patients. (2) GM2 antibody production was associated with a prolonged disease-free interval and survival. (3) Comparison of the two arms of this trial as randomized fails to show a statistically significant improvement in disease-free interval or survival for patients treated with GM2/BCG vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pukel, C. S., Lloyd, K. O., Travassos, L. R., Dippold, W. G., Oettgen, H. F., & Old, L. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1133 · Cited by 576
Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
Cahan, L. D., Irie, R. F., Singh, R., Cassidenti, A., & Paulson, J. C. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7629 · Cited by 242
GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling, F., Shang, A., Calves, M. J., Zhang, S., Ren, S., Yu, R. K., Oettgen, H. F., & Livingston, P. O. (1994) · PubMed · Cited by 179
Self-citationPrognostic Factors in Patients With Melanoma Metastatic to Axillary or Inguinal Lymph Nodes
Coit, D. G., Rogatko, A., & Brennan, M. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199111000-00014 · Cited by 174
Immunogenicity of melanoma‐associated gangliosides in cancer patients
Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., & Morton, D. L. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910350507 · Cited by 166
Gangliosides of Human Melanoma2
Tsuchida, T., Saxton, R. E., Morton, D. L., et al. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/78.1.45 · Cited by 163
Awwad, M., & North, R. J. (1989) · PubMed · Cited by 149
Ganglioside antigens expressed by human cancer cells.
Ritter, G., & Po, L. (1991) · PubMed · Cited by 76
Self-citation
Cited by
Chang, A. E., Karnell, L. H., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g · Cited by 1,663
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Metadata
- Authors
- Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., & Ritter, G.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-05
- Volume
- 12
- Issue
- 5
- Pages
- 1036-1044
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1866549327
- Cited by
- 516
- References
- 8
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. https://app.cochat.ai/papers/10.1200/jco.1994.12.5.1036
- The paper
- Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., & Ritter, G. (1994). Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.5.1036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.